United Services Automobile Association Buys New Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

United Services Automobile Association purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,882 shares of the biotechnology company’s stock, valued at approximately $255,000.

A number of other institutional investors and hedge funds have also bought and sold shares of ADMA. Larson Financial Group LLC purchased a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $31,000. GAMMA Investing LLC boosted its position in ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 967 shares during the last quarter. National Bank of Canada FI bought a new position in ADMA Biologics in the 3rd quarter valued at $35,000. Vision Financial Markets LLC purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at $51,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of ADMA Biologics during the 3rd quarter worth $62,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Stock Up 2.6 %

ADMA stock opened at $20.32 on Tuesday. The stock has a fifty day moving average of $16.84 and a 200-day moving average of $18.07. ADMA Biologics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $23.64. The company has a market capitalization of $4.80 billion, a price-to-earnings ratio of 72.57 and a beta of 0.60. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.